source
- Merck and Moderna plan to seek approval for personalized mRNA melanoma vaccine after Phase 3 shows delayed recurrenceAt the 2026 STAT Summit, Merck and Moderna outlined their partnership to combine Keytruda with a personalized mRNA cancer vaccine aimed at melanoma patients. In a large Phase 3 trial, the vaccine…
- Virginia secures $12.6 billion in onshoring commitments as Trump pushes drugmakers to expand US manufacturingThe Commonwealth of Virginia is emerging as a leading destination for pharmaceutical manufacturing investments after recent policy encouragement from the White House. President Donald Trump has ur…